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Introduction
Upper tract urothelial carcinoma (UTUC) accounts for 
5% of all urothelial carcinomas with an estimated annual 
incidence of 1 to 2 cases per 100,000 inhabitants (1). 
Sometimes considered the twin of urothelial carcinoma 
of the bladder (UCB) (2), UTUC is now considered 
a distinct entity by SIU and EAU guidelines (3). The 
annual number of UTUC-related publications has almost 
tripled over the last 10 years (Figure 1). First symposia 
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and working groups such as the Upper Tract Urothelial 
Carcinoma Collaboration, French Collaborative National 
Working-Group on UTUC, and Canadian Upper Tract 
Collaboration reflect growing interest for UTUC.
Basic research and collaborative efforts have contributed 
to improve our knowledge on the natural history of 
UTUC. Improvements in technologies and extrapolation 
from UCB management, have greatly contributed to 
progress in UTUC management. The low incidence of 
the disease is, however, a limit for studies with high level 
of evidence. Prediction models have been developed to 
help physicians with evidence based personalized clinical 
decision making (4). 
The objective of this review was to provide insights in 
current advances in UTUC tumorigenesis, risk stratification 
and treatment, and to highlight unmet needs of UTUC as 
we know it today.
Methods and evidence acquisition
A non-systematic Medline/PubMed literature search 
was performed using a combination of the terms “upper 
tract urothelial carcinoma” with different keywords. 
To select relevant articles, reviews and editorials from 
English literature, the following keywords were used for 
the needs of the different sections of the manuscript: (I) 
“epidemiology”, “risk factors”, and “biology”; (II) “staging” 
and “risk stratification”; (III) “conservative treatment”, 
“nephro-ureterectomy” and “lymphadenectomy”; (IV) 
“neo-adjuvant treatment” and “adjuvant treatment”. Time 
period included articles published between January 2000 
and January 2015. Additional informative articles were 
collected by cross referencing the bibliography of previously 
selected articles.
Evidence synthesis
Soil and seed
Specific risk factors
UTUC has long been considered the twin tumor of UCB. 
Therefore, past and current practices are mainly derived 
from UCB management. However, several epidemiologic 
and basic research studies have clearly demonstrated 
UTUC presents specific anatomical, biological, clinical and 
pathological features (2). These tumors are less frequent 
than UCB, more invasive at diagnosis, and have a male to 
female ratio of 2:1 (2).
UCB and UTUC share common risk factors like smoking 
and exposure to aromatic amines. Specific risk factors have 
been identified in UTUC. It has been recently shown that 
UTUC is associated with Balkan endemic nephropathy, a 
disease linked to aristolochic acid (AA) exposure leading 
to DNA-adducts with specific genetic signatures such as 
a TP53 A to T transversion (5-7). Epidemiologic studies 
estimated that one third of the Taiwanese population has 
been exposed to AA, as it is an integral part of Chinese 
herbal medicine (8). This exposure also exists in China, 
other parts of Asia, as well as in ayurvedic medicine in India. 
Genetic features could also represent specific risk factors to 
develop UTUC even with a relatively low environmental 
risk exposure to known carcinogens.
Some UTUC have a hereditary predilection belonging 
to the hereditary nonpolyposis colorectal carcinoma 
(HNPCC) tumors spectrum (9). Alterations of mismatch 
repair genes, responsible for HNPCC, could also be 
involved in sporadic UTUC as a potential initiating event 
(10,11). It has been recommended to test all patients with 
UTUC who are less than 60 years old, have a personal 
history of an HNPCC-associated cancer, a first-degree 
relative <50 years of age with HNPCC-associated cancer, or 
two first-degree relatives with HNPCC-associated cancer, 
to identify hereditary cancers that have been misclassified 
as sporadic cancers (3). Studies on genetic variations 
in the population have also identified specific genetic 
polymorphisms associated with a higher risk of UTUC (12,13). 
Sasaki et al. reported DNA repair gene polymorphisms 
could have a prognostic value since more than two variant 
alleles in these genes was associated with a significant better 
overall survival (OS) and cancer specific survival (CSS) after 
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Figure 1 Annual number of publications related to “upper tract 
urothelial carcinoma”.
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radical nephroureterectomy (RNU) (14). Such genetic risk 
markers of UTUC could help identify patients who have an 
increased risk of developing UTUC but also those who are 
more likely to harbor biologically aggressive disease. 
Molecular biomarkers
Several tissue, blood, genetic or urine based biomarkers, 
such as microsatellite instability (MSI) of the tumor, p53, 
E-cadherin, HIF1alpha, and ki-67 have been proposed to 
help in the prognostication of UTUC (15). Krabbe et al. 
reported in 475 patients treated with RNU that Ki-67 was 
an independent prognosticator of recurrence free survival 
(RFS) and CSS for high grade tumors (16). Bagrodia et al. 
similarly demonstrated that both PI3K and cyclin D, two 
mTOR biomarkers, were associated with adverse pathologic 
results and worse oncological outcomes in a cohort of 620 
patients who underwent RNU or partial ureterectomy (17). 
To date, none of these potential biomarkers have been 
integrated to clinical practice or predictive models. While 
there are many challenges to the stepwise assessment of 
new biomarkers before integration into clinical care (18), 
in UTUC, biomarkers are mainly needed to help risk 
stratify the disease in order to identify patients who may 
benefit from kidney-sparing management, neoadjuvant 
chemotherapy (NC), or extended lymphadenectomy. These 
initial studies were done on RNU specimens, so they help 
understand the biological potential of these biomarkers 
post-operatively but not in the pre-RNU setting. After 
RNU, adjuvant chemotherapy (AC) is not established for 
the reasons we discussed below. The validation of these new 
molecular and genetic characteristics may help physicians 
better appraise patient and tumor identities to guide clinical 
decisions and design a personalized approach to some cases. 
Still, biomarkers are urgently needed in the pre-RNU 
setting. Biomarkers that can be evaluated in small tissue 
samples obtained by endoscopic biopsy may help overcome 
the shortcomings of current staging in UTUC through 
refined biomarker-guided risk stratification.
“Plant anatomy and morphology”
Imaging and biopsy
Imaging and ureteroscopic biopsy now play a critical role 
to define stage and grade of UTUC, which are the most 
accurate independent factors of outcome (15). However, 
despite technological advances, current modalities 
yield limited samples that preclude optimal staging and 
grading. Multi-detector computed tomography urography 
(MDCTU) with images during excretory phase (10-15 min) 
is the standard technique used for staging today (3). Its 
accuracy to stage the tumor ranges from 59% to 88% 
(19,20). Assessment of nodal involvement by MDCTU 
is even less accurate since only 60% of the patients with 
positive lymph nodes (LNs) at LN dissection (LND) are 
considered N+ on preoperative imaging (21). Nevertheless, 
if invasion is seen on MDCTU, it indicates at least muscle 
invasive disease (22). In addition, hydronephrosis has also 
been associated with invasive disease which may not benefit 
from kidney-sparing management (23).
Flexible ureteroscopy has revolutionized preoperative 
evaluation of UTUC allowing to visualize all upper urinary 
tract and to perform tumor biopsy. There are anatomical 
and instrumental l imitations to sample the tumor 
adequately (24). Even when the biopsy can be properly 
analyzed, the accuracy of biopsy to define T stage is limited. 
Smith et al. reported a stage discrepancy between final RNU 
pathology and endoscopic biopsy in 38% of the cases (25). 
Biopsy is more efficient regarding grading assessment with 
an accuracy ranging from 69% to 91% when compared with 
RNU pathology (26). Biopsy grading can enhance T staging 
evaluation: 68-100% of grade 1 biopsies are associated 
with ≤ pT1 tumors while 62-100% of biopsies with grade 3 
correctly predict muscle invasive stage (≥ pT2) (26).
To improve T staging by imaging and compensate 
the paucity of current pathological data from biopsy, 
new modalities of acquisition and evaluation have been 
developed. Matin et al. tested a promising endoluminal 
ultrasound (US) (27). In this pilot study, seven patients 
with UTUC underwent RNU after endoluminal US 
evaluation to stage the tumor. PPV and NPV for invasive 
disease status were 66.7% and 100%, respectively. Other 
technologies such as optical coherence tomography and 
confocal laser endomicroscopy are under evaluation 
(28,29). Preliminary reports suggest multiparametric MRI, 
especially ADC, could also be useful tools for staging 
and grading the tumor (30,31). Sassa et al. evaluated 
11C-choline positron emission tomography-computed 
tomography (PET/CT) for primary diagnosis and staging 
of UTUC and demonstrated encouraging results, especially 
regarding nodal evaluation. In this study, among 12 
patients with UTUC on final pathology and pre-operative 
PET/CT, 11 had choline tumor uptake on pre-operative 
PET/CT. LN or distant metastases were diagnosed in five 
patients on pre-operative PET/CT and all metastatic sites 
displayed choline uptake (32). 
To improve the quality of biopsies, new instrumental 
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methods have been tested and showed that tumor removal 
using baskets could better determinate tumor grade in 
some cases (33,34). New technologies such as narrow band 
imaging (NBI) and high definition digital ureteroscopy can 
also help better characterize tumor characteristics (35).
Predictive models
To overcome current limited accuracy of imaging and 
biopsy sampling and to combine all available data to 
improve outcome prediction, multi-institutional clinical 
research groups have developed preoperative predictive 
models to guide clinical decision-making (36). Favaretto 
et al. proposed a model based on the combination of data 
from imaging (local invasion and hydronephrosis) and 
ureteroscopy (tumor location and high grade at biopsy) (22). 
Margulis et al. combined grade, architecture and tumor 
location (37). These models were able to predict non 
organ confined disease with an accuracy of 70% and 77%, 
respectively. Brien et al. proposed a simple model based on 
the presence of hydronephrosis, high grade at biopsy and 
positive cytology. The positivity or negativity of all three 
features was able to predict the muscle invasion with 89% 
PPV and 100% NPV (38). 
To date, guidelines propose a risk stratification on 
low risk and high risk tumors based on pre-operative 
parameters to guide therapeutic management of patients 
with UTUC (3,39). This decision making definition relies 
on relatively small studies and experts’ opinion. These 
predictive models represent evidence based data that may 
be integrated in treatment decision algorithms. However, 
no external validation of these models has been published 
yet. Therefore, large and multicenter external validation of 
these models are the first step before considering their use 
in the management of UTUC.
“The best harvest”
Kidney sparing approach using flexible ureteroscopy
Kidney sparing management of UTUC was historically 
limited to imperative indications (renal insufficiency or 
solitary functional kidney). The previously described 
concept of “low risk” tumors, the high percentage of pTa 
tumors at time of RNU, and the development of flexible 
ureterorenoscopy and novel instrumentations lead to a shift 
of the indications to elective cases (when the contralateral 
kidney is functional) (40). The tumor has to be resectable 
and with a low risk of recurrence and progression, and 
the patient has to understand that a close follow up is 
necessary (3). This can be achieved with flexible/semi-
rigid ureteroscopy today. Open and percutaneous resection 
of tumors of the renal pelvis or calices have almost 
disappeared (3). Distal ureteral segmentectomy remains, 
however, an option for tumors of the distal ureter or in case 
of ureteroscopic failure (41).
Recently, using the Surveillance, Epidemiology, and End 
Results (SEER) database, Simhan et al. reported similar CSS 
with RNU and kidney sparing procedure (KSP), including 
ureteral segmentectomy and endoscopic KSP (42). 
Patients treated with KSP were older with a greater 
proportion of grade 1 tumors and underwent segmental 
ureterectomy in 62.5% of cases. To date, oncological 
outcomes of endoscopic KSP with percutaneous resection 
and/or flexible ureteroscopy tumor ablation have been 
compared to RNU in nine non-randomized studies (43-51). 
A recent meta-analysis included eight of these studies and 
revealed no difference in terms of OS and CSS between 
both strategies (52). These studies were all retrospective 
with small cohorts and limited follow-up. Selection bias 
was clearly a major limitation since most tumors in the 
KSP group were unifocal, <2 cm and low grade, in contrast 
with a higher incidence of invasive tumors in the RNU 
group. Local recurrence rate, a major issue in endoscopic 
conservative management, ranged from 6% to 71% in 
these heterogeneous cohorts. Results were so variable 
that no reliable RFS meta-analysis could be performed. 
Yakoubi et al. partly related the high heterogeneity among 
studies to differences in expertise of endoscopy between 
centers (52). Progression rate, another major concern 
regarding conservative management, remains unclear 
because of the inability to accurately grade and stage 
UTUC. Grade and stage migration during follow up has 
been estimated to reach 19% and 14%, respectively, and 
varied widely according grade at first biopsy (26). A delayed 
RNU is finally performed in 28-43% patients initially 
treated endoscopically (26). A major issue to address is the 
oncologic impact of such delayed radical treatment. Two 
studies compared delayed RNU after endoscopic KSP to 
immediate RNU and reported similar oncologic outcomes 
(53,54). However, these results should be considered with 
caution due to small populations and short follow-up.
Many improvements with digital ureteroscopes such 
as NBI and photodynamic diagnosis are currently under 
evaluation (35). These new technologies could help better 
diagnose UTUC but also perform a complete tumoral 
ablation during endoscopic KSP. Despite the lack of 
prospective randomized studies, the differential indications 
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for KSP versus RNU seem reasonable based on the available 
evidence in order to provide optimal risk-based therapy for 
the individual patient.
Radical nephro-ureterectomy
Because of the limits of KSP and since more than 60% of 
tumors are invasive at presentation, RNU still remains the 
standard treatment for the majority of UTUC (3). To ensure 
negative margin, complete removal of the ureter including 
a bladder cuff is mandatory during RNU. In high risk 
UTUC (pT3N0, pT4N0 and/or N+ and/or M+), positive 
margins have been identified as an independent prognostic 
factor for CSS and OS (55). Lughezzani et al. showed that 
avoiding bladder cuff excision increased cancer specific 
mortality (CSM), especially in high risk UTUC (56). 
Several approaches have been proposed to perform 
bladder cuff excision with no difference in RFS, CSS, 
and OS between transvesical, extravesical, or endoscopic 
approaches in a large multicenter study of 2,681 patients 
treated with RNU (57). However, endoscopic approach 
was associated with a higher risk of intravesical recurrence. 
Recently, Kapoor et al. reported an improved overall and 
intravesical RFS with open intravesical excision of the distal 
ureter compared with endoscopic but also extravesical 
approaches (58). 
Similarly to other fields of urology, laparoscopy and 
robotic assistance have been adopted to perform RNU. 
Robotic assisted RNU is still in its infancy and comparative 
studies are scarce (59,60). Conversely, many studies have 
compared laparoscopic RNU (LRNU) to open RNU 
(ORNU), and a recent meta-analysis reported similar 
oncologic outcome (61). Caution should be advocated 
especially in locally advanced disease since LRNU is 
generally performed in favorable-risk patients (62). Indeed, 
Fairey et al. reported that LRNU may be associated with 
poorer RFS compared to ORNU in a study of 849 patients 
(403 ORNU vs. 446 LRNU) (P=0.06) (63). In the only 
randomized controlled trial, Simone et al. found CSS and 
metastasis free survival were significantly different between 
the two procedures for pT3 tumors, in favor of ORNU 
(P=0.039 and P=0.004, respectively) (64). However, this 
and other studies were limited by their small size and other 
potential biases of selection or expertise, but one main 
limitation may be the use or extent of LND during LRNU. 
The importance of LND remains a question of debate, 
yet all the evidence shows improved outcomes with higher 
number of LN removed, specially in LN negative 
patients (65). Capitanio et al. reported that LND was not 
commonly performed during ORNU and LRNU [42% 
and 24% of cases, respectively (62)]. Guidelines advocate 
LND in RNU for two reasons: (I) improve prognostication; 
(II) a potential therapeutic effect (3). Indeed, LN status 
is one of the most powerful predictor of CSS in patients 
treated with RNU, possibly guiding treatment decision 
for follow-up scheduling and AC (66). Roscigno et al. 
estimated that removal of eight LNs was the critical cut off 
to reach a prognostic significance and a 75% probability to 
correctly stage the patients (67). Therapeutic effect remains, 
however, unclear. A potential survival benefit in patients 
who underwent a LND during RNU has been reported in 
several monocentric studies with small cohorts (68-70). Two 
retrospective studies in large cohorts of patients reported 
this benefit could only be valuable in muscle invasive or 
locally advanced UTUC (71,72). Indeed, the risk of LN 
involvement is limited in Ta T1 UTUC, probably less than 
5% (65,73). Recently, Yang et al. included 6,000 patients 
in a meta-analysis and confirmed a benefit of LND only 
in the group of patients with muscle invasive tumors (74). 
One question that remains unclear in these studies is the 
template for LND. Kondo et al. proposed a template 
for LND according to tumor location in the upper two-
thirds of ureter, or in the lower third of the ureter (68). 
The former implies a dissection of iliac vessels, the latter a 
dissection of the aorta or the vena cava that could limit its 
performance minimally-invasively.
Therefore, prospective comparative studies are 
mandatory to assess the oncologic outcomes according to 
surgical approach and the extent of LND. Futures studies 
with RNU should match patients for grade and stage, but 
also for surgical approach. Strict definitions of the extent of 
LND using predefined templates will be necessary to make 
evidence-based recommendations. 
“Prevent growth and regrowth”
Local instillations
One major concern with each management is  the 
prediction, prevention and treatment of disease recurrence. 
Urothelial carcinoma can either recur in the bladder, 
contralateral ureter and/or in the ipsilateral ureter if KSP 
has been attempted. 
After KSP, recurrence rate in the upper tract can be 
reported in up to 70% of the cases (52). Instillations of 
topical agents in the upper tract have been proposed 
to decrease this risk. Different approaches have been 
reported (percutaneous nephrostomy, retrograde 
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catheterisation and vesico-ureteral reflux) with bacille 
calmette guerin (BCG) and mitomycin C (MMC) 
(75,76). BCG instillations for carcinoma in situ (CIS) 
may be the only one with sufficient evidence today. 
Only one study compared BCG instillation and RNU 
for CIS in 11 and 6 patients, respectively, and reported 
no significant difference in 5-year RFS and CSS (77). 
Topical instillations with BCG and MMC have been also 
reported as therapy after endoscopic management of 
Ta/T1 UTUC. Rastinehad et al. performed the largest 
comparative study with adjuvant antegrade BCG therapy 
after percutaneous resection and demonstrated no benefit 
in terms of recurrence and progression rates (78). These 
studies were retrospective, mostly non comparative, and 
included small cohorts treated mainly by percutaneous 
resection. These limitations preclude any conclusion 
regarding the use of instillations in the upper tract for 
UTUC after conservative treatment. Therefore, new 
studies should investigate its efficacy but also the best 
way to administrate it in the era of flexible ureteroscopic 
management.
Instillation of post-operative topical agents in the bladder 
have also been proposed to decrease the risk of intravesical 
recurrence after RNU. Indeed, 30% to 50% of patients 
will develop UCB during the first 5 years after RNU for 
UTUC (79). O’Brien et al. demonstrated, in a prospective 
multicentre randomized study, that a single post-operative 
intravesical dose of MMC after RNU decreased the relative 
risk of bladder tumor by 40% within the first year (80). In 
a phase II trial using intravesical pirarubicin (THP) within 
48 h after RNU, Ito et al. reported similar results (81). 
Xylinas et al. developed a tool to identify the patients most 
likely to benefit from immediate post RNU intravesical 
chemotherapy (82). No study on the role of early post 
operative bladder instillation has been yet published after 
endoscopic management. Therefore, high level of evidence 
regarding the usefulness of post operative instillation of 
MMC after RNU now exits but further evaluation is needed 
to conclude on its efficacy after KSP management, another 
area of high likelihood of benefit.
Chemotherapy
Systemic NC before radical cystectomy has demonstrated 
survival benefit in patients with T2-4 N0 M0 UCB with 
high level of evidence (83). To date, no level 1 evidence 
exists to state on the role of peri-operative chemotherapy 
in UTUC. A recent review and meta-analysis identified 
ten studies that investigated the role of chemotherapy in 
an adjuvant setting (84). All but one were retrospective 
studies. These studies harbored many potential biases with 
most patients who received AC having worse prognostic 
factors and more likely to have LN metastasis. Conversely, 
patients receiving AC may have better renal function and 
performance status. Meta-analysis demonstrated only 
a statistically significant benefit for OS and disease free 
survival (DFS) among the three studies using cisplatin-
based AC (HR, 0.43; 95% CI, 0.21-0.89; P=0.023). 
Furthermore, recent studies suggested that AC may only 
benefit high risk patients with pT3-4 UTUC and LN 
involvement (85,86). With potential benefit restricted to 
cisplatin based chemotherapy in locally advanced disease, 
the impact of AC appears limited since most patients with 
UTUC will experience renal function loss after RNU, 
becoming ineligible (87). Even before RNU, only 49% of 
patients have a glomerular filtration rate that would allow 
cisplatin based chemotherapy. This rate decreases to 19% 
after RNU.
Potential use and efficacy of chemotherapy in a pre-
operative setting is, therefore, a critical issue. To date, two 
prospective studies assessed the role of NC in patients with 
urothelial carcinoma but only recruited 21 patients with 
UTUC. These studies suggested NC could be associated 
with a significant downstaging. The small cohorts and the 
inaccuracy of current methods to pre-operatively stage the 
tumor limit any conclusion (84). Results from four larger 
retrospective and comparative studies that specifically 
evaluated NC in UTUC have been published so far 
(88-91). Matin et al. reported outcomes of 43 patients 
with high grade UTUC who received NC compared 
to a historical cohort. A significant higher pathologic 
downstaging and a complete response in 14% of patients 
were observed in the NC group (89). In a recent study, 
use of NC in 31 patients was associated with a significant 
improvement of OS and CSS compared to a cohort of 81 
patients who underwent RNU alone (91). Upper Tract 
Urothelial Carcinoma Collaboration group reported as 
well outcome in a large cohort of 313 patients including 18 
patients with biopsy proven LN involvement who received 
NC and demonstrated favorable oncologic outcomes in 
this group: 5-yr DFS and CSS rates of 49% and 44%, 
respectively (88). Considering these two last studies, a 
recent meta-analysis reported a CSS benefit of 59% with 
NC (HR, 0.41; 95% CI: 0.22-0.76; P=0.005) (84). These 
retrospective data suggest that all eligible patients should be 
proposed cisplatin combination chemotherapy in UTUC. 
Which patients are most likely to benefit from NC remains 
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to be defined. Patients with clinically suspect LN should 
receive definitive chemotherapy and a RNU in case of 
response. However, the level of evidence of the studies does 
not allow any firm conclusion. Further prospective trials are 
needed to assess the role of peri-operative chemotherapy 
in UTUC. One randomized controlled phase 3 trial, the 
peri-operative chemotherapy versus surveillance in upper 
tract urothelial cancer (POUT) trial, is ongoing (92). This 
trial will randomize 345 patients undergoing RNU for 
UTUC between adjuvant platin-based chemotherapy and 
surveillance. Results from phase 2 trials that investigate 
impact of neoadjuvant gemcitabine in patients with high 
grade or T2-T4 N0/X M0 UTUC before RNU will 
probably help us further to define the place of perioperative 
chemotherapy in UTUC.
Predictive models
The lack of randomized trials and reliable preoperative 
staging and grading evaluation leads to complex decision 
making in UTUC management. Intense collaborative 
and multi-institutional efforts resulted in propositions of 
predictive tools. To date, three pre-operative models have 
been proposed to predict muscle invasive and non-organ-
confined UTUC (22,23,37,38). We previously discussed 
the usefulness of these models to decide between KSP and 
RNU. Other predictive models using pre-operative data 
represent promising tools. Two models based on imaging, 
urine cytology, or neutrophil count demonstrated significant 
ability to predict RFS and CSS (93,94). To manage the 
potential risk of renal function loss after RNU, several 
prognostic factors have been identified and corresponding 
predictive models constructed to identify patients that 
would not be suitable for post-operative chemotherapy 
(95-97). These prediction tools could help physicians 
identify patients who may benefit from neoadjuvant medical 
treatments in UTUC or LND during surgery.
Several postoperative prognostic risk factors after 
UTUC have been identified and were combined to propose 
post-operative prediction tools (36). Jeldres et al. were the 
first to propose a post-operative nomogram for UTUC. 
Within a cohort of almost 6,000 patients from the SEER 
database, a model based on age, tumor stage, tumor grade, 
and LN status predicted 5-year CSS with a discrimination 
of 75.4%. Since this first nomogram, four new models 
have been published. The French collaborative group 
and international UTUC collaboration proposed their 
own models to predict CSS (98,99). Both cohorts (3,387 
patients) were combined and the model predicted 5-year 
CSS with 80% discrimination (100). Recently, Seisen 
et al. proposed a model including only patients without 
NC from both collaborative groups (101). However, to 
date, only one external validation focusing on the French 
collaborative group model has been published (102). Xylinas 
et al. recently published a predictive model of intravesical 
recurrence after RNU (82). Based on age, gender, previous 
history of bladder cancer, tumor location, tumor stage, 
presence of concomitant CIS, and LN status, the model 
discrimination was 68%. With this model, considering a 
risk of intravesical recurrence of 15% at 2 years to perform 
post operative instillation would spare 23% of the patients 
while not preventing only 0.3% of intravesical recurrences. 
These models could be particularly relevant to help 
physicians identifying patients whose disease is more likely 
to recur and therefore benefit from adjuvant therapy. 
Conclusions
Ten years of intense collaborative efforts in basic and clinical 
research have made the natural history of UTUC more 
comprehensible and predictable. Current management is 
based, however, on low level evidence and there are many 
challenges to face in the future. There is a need to clarify 
the role of KSP management, topical agents, LND, and 
perioperative chemotherapy. New further collaborative 
efforts are mandatory to propose ambitious multi-
institutional studies with preferentially prospective design.
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